WX390 plus Toripalimab for STK11-mutated cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a rare type of cervical cancer called gastric-type endocervical adenocarcinoma, and your tumor must have a mutation in the STK11 gene.
- You should be able to take care of yourself (up and about) and have a life expectancy of at least 3 months.
- You must have at least one tumor that can be measured on a scan.
- You cannot have had cancer treatment or major surgery in the last 30 days, or certain infections like HIV, active hepatitis B or C, or lung disease.
- You must be willing to take oral medication and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
This study tests a combination of two oral/injected drugs (topotecan and toripalimab) for people with advanced or recurrent endometrial cancer who have already tried one line of treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Gastric Type Adenocarcinoma (GAS) With STK11 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.